Karvellas Constantine J, Cavazos Jorge, Battenhouse Holly, Durkalski Valerie, Balko Jody, Sanders Corron, Lee William M
Divisions of Hepatology and Critical Care Medicine, University of Alberta, Edmonton, Canada.
Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas.
Clin Gastroenterol Hepatol. 2014 Nov;12(11):1942-9.e1. doi: 10.1016/j.cgh.2014.03.011. Epub 2014 Mar 25.
BACKGROUND & AIMS: We investigated whether antimicrobial prophylaxis alters the incidence of bloodstream infection in patients with acute liver failure (ALF), and whether bloodstream infections affect overall mortality within 21 days after development of ALF.
We performed a retrospective cohort analysis of 1551 patients with ALF enrolled by the US Acute Liver Failure Study Group from January 1998 through November 2009. We analyzed data on infections in the first 7 days after admission and the effects of prophylaxis with antimicrobial drugs on the development of bloodstream infections and 21-day mortality.
In our study population, 600 patients (39%) received antimicrobial prophylaxis and 226 patients (14.6%) developed at least 1 bloodstream infection. Exposure to antimicrobial drugs did not affect the proportion of patients who developed bloodstream infections (12.8% in patients with prophylaxis vs 15.7% in nonprophylaxed patients; P = .12), but a greater percentage of patients who received prophylaxis received liver transplants (28% vs 22%; P = .01). After adjusting for confounding factors, overall mortality within 21 days was associated independently with age (odds ratio [OR], 1.014), Model for End-stage Liver Disease score at admission (OR, 1.078), and vasopressor administration at admission (OR, 2.499). Low grade of coma (OR, 0.47) and liver transplantation (OR, 0.101) reduced mortality. Although bloodstream infection was associated significantly with 21-day mortality (P = .004), an interaction between bloodstream infection and etiology was detected: blood stream infection affected mortality to a greater extent in nonacetaminophen ALF patients (OR, 2.03) than in acetaminophen ALF patients (OR, 1.14).
Based on a large, observational study, antimicrobial prophylaxis does not reduce the incidence of bloodstream infection or mortality within 21 days of ALF. However, bloodstream infections were associated with increased 21-day mortality in patients with ALF-to a greater extent in patients without than with acetaminophen-associated ALF. Our findings do not support the routine use of antimicrobial prophylaxis in patients with ALF.
我们研究了抗菌药物预防性治疗是否会改变急性肝衰竭(ALF)患者血流感染的发生率,以及血流感染是否会影响ALF发生后21天内的总体死亡率。
我们对1998年1月至2009年11月期间美国急性肝衰竭研究组登记的1551例ALF患者进行了回顾性队列分析。我们分析了入院后前7天的感染数据,以及抗菌药物预防性治疗对血流感染发生和21天死亡率的影响。
在我们的研究人群中,600例患者(39%)接受了抗菌药物预防性治疗,226例患者(14.6%)发生了至少1次血流感染。接受抗菌药物治疗并未影响发生血流感染的患者比例(接受预防性治疗的患者为12.8%,未接受预防性治疗的患者为15.7%;P = 0.12),但接受预防性治疗的患者中接受肝移植的比例更高(28%对22%;P = 0.01)。在对混杂因素进行校正后,21天内的总体死亡率与年龄(比值比[OR],1.014)、入院时终末期肝病模型评分(OR,1.078)以及入院时使用血管升压药(OR,2.499)独立相关。轻度昏迷(OR,0.47)和肝移植(OR,0.101)可降低死亡率。虽然血流感染与21天死亡率显著相关(P = 0.004),但检测到血流感染与病因之间存在交互作用:非对乙酰氨基酚所致ALF患者中血流感染对死亡率的影响程度(OR = 2.03)大于对乙酰氨基酚所致ALF患者(OR = 1.14)。
基于一项大型观察性研究,抗菌药物预防性治疗并不能降低ALF患者21天内血流感染的发生率或死亡率。然而,血流感染与ALF患者21天死亡率增加相关——在非对乙酰氨基酚所致ALF患者中比在对乙酰氨基酚所致ALF患者中影响程度更大。我们的研究结果不支持对ALF患者常规使用抗菌药物预防性治疗。